BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 0.3% to $6.54 after the company was awarded a contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease. Share volume was 562,000, compared to an all-day average of 2.5 million
